COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

Abstract As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are prom...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Daniel Junker, Alex Dulovic, Matthias Becker, Teresa R. Wagner, Philipp D. Kaiser, Bjoern Traenkle, Katharina Kienzle, Stefanie Bunk, Carlotta Struemper, Helene Haeberle, Kristina Schmauder, Natalia Ruetalo, Nisar Malek, Karina Althaus, Michael Koeppen, Ulrich Rothbauer, Juliane S. Walz, Michael Schindler, Michael Bitzer, Siri Göpel, Nicole Schneiderhan-Marra
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Portfolio 2022-05-01
Edice:Scientific Reports
On-line přístup:https://doi.org/10.1038/s41598-022-10987-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky